Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › zenagamtide

zenagamtide

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Evaluation of Once Weekly Subcutaneous Zenagamtide for Management of Type 2 Diabetes
Diabetes & Endocrinology RCT
Evaluation of Once Weekly Subcutaneous Zenagamtide for Management of Type 2 Diabetes New weekly injection shows promise for managing Type 2 Diabetes
Zenagamtide, a dual GLP-1 and amylin agonist, demonstrated significant HbA1c reductions in patients with type 2 diabetes over 36 weeks.
A new once-weekly injection showed significant reductions in blood sugar levels for adults living with Type 2 diabetes during a recent clini…
Aug 15, 2026
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Diabetes & Endocrinology Sys. Review
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Frontiers Jul 25, 2026